Clinical trial
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in…
NCT00257478 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00257478 |
|---|---|
| Title | A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate |
| Intervention type | Drug |
| Interventions | YM155 |
| Completion | Mar 1, 2007 |
| First posted | Nov 23, 2005 |
| Last update posted | Jun 7, 2012 |
| Countries | Netherlands, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: